Smad6 inhibits non-canonical TGF-β1 signalling by recruiting the deubiquitinase A20 to TRAF6

Nature Communications

Volumn 4, Issue , 2013, Pages

  Jung, Su Myung ^a   Lee, Ji Hyung ^a   Park, Jinyoung ^b,c   Oh, Young Sun ^a,d   Lee, Sung Kyun ^a   Park, Jin Seok ^a   Lee, Youn Sook ^a   Kim, Jun Hwan ^a   Lee, Jae Young ^a   Bae, Yoe Sik ^a   Koo, Seung Hoi ^c   Kim, Seong Jin ^e   Park, Seok Hee ^a  

^a Sungkyunkwan University   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Korea University   (South Korea)

^d Seoul National University   (South Korea)

^e CHA University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DEUBIQUITINASE; DEUBIQUITINASE A20; MITOGEN ACTIVATED PROTEIN KINASE 14; SMAD6 PROTEIN; SMAD7 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG; CYSTEINE PROTEINASE; DNA BINDING PROTEIN; MAP KINASE KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; SIGNAL PEPTIDE; SMAD6 PROTEIN, MOUSE; TNFAIP3 PROTEIN, MOUSE; UBIQUITIN PROTEIN LIGASE; A20 PROTEIN, MOUSE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CULTURE; HUMAN; HUMAN CELL; LIVER CELL; MOUSE; NONHUMAN; PROTEIN PROTEIN INTERACTION; UBIQUITINATION; ANIMAL; C57BL MOUSE; CYTOLOGY; EPITHELIUM CELL; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; INTESTINE; LIVER; METABOLISM; PHOSPHORYLATION; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION; CELL STRAIN HEK293;

ANIMALIA;

ANIMALS; APOPTOSIS; CYSTEINE ENDOPEPTIDASES; DNA-BINDING PROTEINS; EPITHELIAL CELLS; GENE EXPRESSION REGULATION; HEK293 CELLS; HEPATOCYTES; HUMANS; INTESTINES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER; MAP KINASE KINASE 4; MAP KINASE KINASE KINASES; MICE; MICE, INBRED C57BL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION; SMAD6 PROTEIN; TNF RECEPTOR-ASSOCIATED FACTOR 6; TRANSFORMING GROWTH FACTOR BETA1; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84899604555     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms3562     Document Type: Article

References (60)

1. Derynck, R. & Akhurst, R. J. Differentiation plasticity regulated by TGF-beta family proteins in development and disease. Nat. Cell Biol. 9, 1000-1004 (2007).
2. Massague, J., Seoane, J. & Wotton, D. Smad transcription factors. Genes Dev. 19, 2783-2810 (2005).
3. Moustakas, A. & Heldin, C. H. The regulation of TGFbeta signal transduction. Development 136, 3699-3714 (2009).
4. Shi, Y. & Massague, J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113, 685-700 (2003).
5. Bakin, A. V., Tomlinson, A. K., Bhowmick, N. A., Moses, H. L. & Arteaga, C. L. Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J. Biol. Chem. 275, 36803-36810 (2000).
6. Heldin, C. H., Landstrom, M. & Moustakas, A. Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. Curr. Opin. Cell Biol. 21, 166-176 (2009).
7. Ikushima, H. & Miyazono, K. TGFbeta signalling: A complex web in cancer progression. Nat. Rev. Cancer 10, 415-424 (2010).
8. Lo, R. S., Wotton, D. & Massague, J. Epidermal growth factor signaling via Ras controls the Smad transcriptional co-repressor TGIF. EMBO J. 20, 128-136 (2001).
9. Massague, J. TGFbeta in Cancer. Cell 134, 215-230 (2008).
10. Wakefield, L. M. & Roberts, A. B. TGF-beta signaling: positive and negative effects on tumorigenesis. Curr. Opin. Genet. Dev. 12, 22-29 (2002).
11. Zhang, Y. E. Non-Smad pathways in TGF-beta signaling. Cell Res. 19, 128-139 (2009).
12. Mu, Y., Gudey, S. K. & Landstrom, M. Non-Smad signaling pathways. Cell Tissue Res. 347, 11-20 (2012).
13. Derynck, R. & Zhang, Y. E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425, 577-584 (2003).
14. Sorrentino, A. et al. The type I TGF-[beta] receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat. Cell Biol. 10, 1199-1207 (2008).
15. Yamashita, M. et al. TRAF6 Mediates Smad-Independent Activation of JNK and p38 by TGF-[beta]. Mol. Cell 31, 918-924 (2008).
16. Landstrom, M. The TAK1-TRAF6 signalling pathway. Int. J. Biochem. Cell Biol. 42, 585-589 (2010).
17. Blobe, G. C., Schiemann, W. P. & Lodish, H. F. Role of transforming growth factor beta in human disease. N. Engl. J. Med. 342, 1350-1358 (2000).
18. Nakao, A. et al. Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 389, 631-635 (1997).
19. Hayashi, H. et al. The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling. Cell 89, 1165-1173 (1997).
20. Imamura, T. et al. Smad6 inhibits signalling by the TGF-beta superfamily. Nature 389, 622-626 (1997).
21. Ebisawa, T. et al. Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation. J. Biol. Chem. 276, 12477-12480 (2001).
22. Kavsak, P. et al. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol. Cell 6, 1365-1375 (2000).
23. Murakami, G., Watabe, T., Takaoka, K., Miyazono, K. & Imamura, T. Cooperative inhibition of bone morphogenetic protein signaling by Smurf1 and inhibitory Smads. Mol. Biol. Cell 14, 2809-2817 (2003).
24. Lee, Y. S. et al. Smad7 and Smad6 bind to discrete regions of Pellino-1 via their MH2 domains to mediate TGF-beta1-induced negative regulation of IL-1R/ TLR signaling. Biochem. Biophys. Res. Commun. 393, 836-843 (2010).
25. Choi, K. C. et al. Smad6 negatively regulates interleukin 1-receptor-Toll-like receptor signaling through direct interaction with the adaptor Pellino-1. Nat. Immunol. 7, 1057-1065 (2006).
26. Lee, Y. S. et al. Smad6-specific recruitment of Smurf E3 ligases mediates TGF-beta1-induced degradation of MyD88 in TLR4 signalling. Nat. Commun. 2, 460 (2011).
27. Park, S. H. Fine tuning and cross-talking of TGF-beta signal by inhibitory Smads. J. Biochem. Mol. Biol. 38, 9-16 (2005).
28. Eichhorn, P. J. et al. USP15 stabilizes TGF-beta receptor I and promotes oncogenesis through the activation of TGF-beta signaling in glioblastoma. Nat. Med. 18, 429-435 (2012).
29. Wicks, S. J. et al. The deubiquitinating enzyme UCH37 interacts with Smads and regulates TGF-beta signalling. Oncogene 24, 8080-8084 (2005).
30. Edlund, S. et al. Transforming growth factor-beta1 (TGF-beta)-induced apoptosis of prostate cancer cells involves Smad7-dependent activation of p38 by TGF-beta-activated kinase 1 and mitogen-activated protein kinase kinase 3. Mol. Biol. Cell 14, 529-544 (2003).
31. Boone, D. L. et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat. Immunol. 5, 1052-1060 (2004).
32. Shembade, N., Ma, A. & Harhaj, E. W. Inhibition of NF-kappaB signaling by A20 through disruption of ubiquitin enzyme complexes. Science 327, 1135-1139 (2010).
33. Fan, Y. et al. Lysine 63-linked polyubiquitination of TAK1 at lysine 158 is required for tumor necrosis factor alpha-and interleukin-1beta-induced IKK/NF-kappaB and JNK/AP-1 activation. J. Biol. Chem. 285, 5347-5360 (2010).
34. Reiley, W. W. et al. Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T cell responses. J. Exp. Med. 204, 1475-1485 (2007).
35. Kovalenko, A. et al. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 424, 801-805 (2003).
36. Bosanac, I. et al. Ubiquitin binding to A20 ZnF4 is required for modulation of NF-kappaB signaling. Mol. Cell 40, 548-557 (2010).
37. Skaung, B. et al. Direct, noncatalytic mechanism of IKK inhibition by A20. Mol. Cell 44, 559-571 (2011).
38. Verhelst, K. et al. A20 inhibits LUBAC-mediated NF-kappaB activation by binding linear polyubiquitin chains via its zinc finger 7. EMBO J. 31, 3845-3855 (2012).
39. Tokunaga, F. et al. Specific recognition of linear polyubiquitin by A20 zinc finger 7 is involved in NF-kappaB regulation. EMBO J. 31, 3856-3870 (2012).
40. Heidari, N. et al. Glucocorticoid-mediated BIM induction and apoptosis are regulated by Runx2 and c-Jun in leukemia cells. Cell Death Dis. 3, e349 (2012).
41. Heyninck, K. & Beyaert, R. The cytokine-inducible zinc finger protein A20 inhibits IL-1-induced NF-kappaB activation at the level of TRAF6. FEBS Lett. 442, 147-150 (1999).
42. Hata, A., Lagna, G., Massagué, J. & Hemmati-Brivanlou, A. Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor. Genes Dev. 12, 186-197 (1998).
43. Ishida, T. et al. Identification of TRAF6, a novel tumor necrosis factor receptorassociated factor protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region. J. Biol. Chem. 271, 28745-28748 (1996).
44. Ma, A. & Malynn, B. A. A20: linking a complex regulator of ubiquitylation to immunity and human disease. Nat. Rev. Immunol. 12, 774-785 (2012).
45. Yu, L., Hebert, M. C. & Zhang, Y. E. TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J. 21, 3749-3759 (2002).
46. Moustakas, A. & Heldin, C. H. Non-Smad TGF-beta signals. J. Cell Sci. 118, 3573-3584 (2005).
47. Yan, X. & Chen, Y. G. Smad7: not only a regulator, but also a cross-talk mediator of TGF-beta signalling. Biochem. J. 434, 1-10 (2011).
48. Wertz, I. E. et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 430, 694-699 (2004).
49. Trompouki, E. et al. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 424, 793-796 (2003).
50. Verstrepen, L. et al. ABINs: A20 binding inhibitors of NF-kappaB and apoptosis signaling. Biochem. Pharmacol. 78, 105-114 (2009).
51. Verstrepen, L. et al. TAX1BP1, a ubiquitin-binding adaptor protein in innate immunity and beyond. Trends Biochem. Sci. 36, 347-354 (2011).
52. Lim, J. H. et al. CYLD negatively regulates transforming growth factor-betasignalling via deubiquitinating Akt. Nat. Commun. 3, 771 (2012).
53. Arvelo, M. B. et al. A20 protects mice from D-galatosamine/lipopolysaccharide acute toxic lethal hepatitis. Hepatology 35, 535-543 (2002).
54. Longo, C. R. et al. A20 protects mice from lethal radical hepatectomy by promoting hepatocyte proliferation via a p21waf1-dependent mechanism. Hepatology 42, 156-164 (2005).
55. Ramsey, H. E. et al. A20 protects mice from lethal liver ischemia/reperfusion injury by increasing peroxisome proliferate-activated receptor-alpha expression. Liver. Transpl. 15, 1613-1621 (2009).
56. Daniel, S. et al. A20 protects endothelial cells from TNF-, Fas-, and NKmediated cell death by inhibiting caspase 8 activation. Blood 104, 2376-2384 (2004).
57. Malhi, H., Guicciardi, M. E. & Gores, G. J. Hepatocyte death: A clear and present danger. Physiol. Rev. 90, 1165-1194 (2010).
58. Takeuchi, O. & Akira, S. Pattern recognition receptors and inflammation. Cell 140, 805-820 (2010).
59. Dennler, S. et al. Direct binding of Smad3 and Smad4 to critical TGF betainducible elements in the promoter of human plasminogen activator inhibitortype I gene. EMBO J. 17, 3091-3100 (1998).
60. Koo, S. H. et al. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 437, 1109-1111 (2005).